Evotec SE (EVO)

12.61 +0.19 (+1.53%) At close: 04:00PM EDT

Evotec SE

Essener Bogen 7
Hamburg 22419
Germany
49 40 560 81 0
https://www.evotec.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees: 4,198

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Werner Lanthaler M.B.A., MBA, MPA, Ph.D.	Chairman of Management Board & CEO	1.1M	N/A	1968
Mr. Enno Spillner	CFO & Member of Management Board	631.04k	N/A	1970
Dr. Cord Dohrmann Ph.D.	Chief Scientific Officer & Member of Management Board	822.01k	N/A	1964
Dr. Craig Johnstone	COO & Member of Management Board	641.42k	N/A	1970
Ms. Anja Bosler	Principal Accounting Officer and Sr. VP of Group Accounting	N/A	N/A	N/A
Mr. Volker Braun	Sr. VP and Global Head of Investor Relations & ESG	N/A	N/A	N/A
Dr. Christian Dargel	EVP Global Head of Legal & Compliance	N/A	N/A	N/A
Gabriele Hansen	Sr. VP of Corp. Communications, Marketing & Investor Relations	N/A	N/A	N/A
Ms. Monika Conradt	Global Head of HR	N/A	N/A	N/A
Dr. Ian M. Hunneyball	Sr. VP of Programme Management & Clinical Operations	N/A	N/A	1950

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Corporate Governance

Evotec SE’s ISS Governance QualityScore as of May 1, 2022 is 5. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 1; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.